{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:01:22Z","timestamp":1782226882056,"version":"3.54.5"},"reference-count":26,"publisher":"American Society of Hematology","issue":"23","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Coronavirus disease 2019 (COVID-19) is an illness resulting from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that emerged in late 2019. Patients with cancer, and especially those with hematologic malignancies, may be at especially high risk of adverse outcomes, including mortality resulting from COVID-19 infection. The ASH Research Collaborative COVID-19 Registry for Hematology was developed to study features and outcomes of COVID-19 infection in patients with underlying blood disorders, such as hematologic malignancies. At the time of this report, data from 250 patients with blood cancers from 74 sites around the world had been entered into the registry. The most commonly represented malignancies were acute leukemia (33%), non-Hodgkin lymphoma (27%), and myeloma or amyloidosis (16%). Patients presented with a myriad of symptoms, most frequently fever (73%), cough (67%), dyspnea (50%), and fatigue (40%). Use of COVID-19\u2013directed therapies, such as hydroxychloroquine (n = 76) or azithromycin (n = 59), was common. Overall mortality was 28%. Patients with a physician-estimated prognosis from the underlying hematologic malignancy of &amp;lt;12 months at the time of COVID-19 diagnosis and those with relapsed\/refractory disease experienced a higher proportion of moderate\/severe COVID-19 disease and death. In some instances, death occurred after a decision was made to forgo intensive care unit admission in favor of a palliative approach. Taken together, these data support the emerging consensus that patients with hematologic malignancies experience significant morbidity and mortality resulting from COVID-19 infection. Batch submissions from sites with high incidence of COVID-19 infection are planned to support future analyses.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020003170","type":"journal-article","created":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T15:30:50Z","timestamp":1607182250000},"page":"5966-5975","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":131,"title":["Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub"],"prefix":"10.1182","volume":"4","author":[{"given":"William A.","family":"Wood","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna S.","family":"Neuberg","sequence":"additional","affiliation":[{"name":"Department of Data Science, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Colton","family":"Thompson","sequence":"additional","affiliation":[{"name":"ASH Research Collaborative, Washington, DC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Tallman","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkael A.","family":"Sekeres","sequence":"additional","affiliation":[{"name":"Leukemia Program, Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie H.","family":"Sehn","sequence":"additional","affiliation":[{"name":"British Columbia Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada;"},{"name":"Division of Medical Oncology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2892-2643","authenticated-orcid":false,"given":"Aaron D.","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan A.","family":"Pennell","sequence":"additional","affiliation":[{"name":"Lung Cancer Program, Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3856-7937","authenticated-orcid":false,"given":"Charlotte M.","family":"Niemeyer","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology and Oncology, Medical Center Freiburg, Freiburg, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Tucker","sequence":"additional","affiliation":[{"name":"ASH Research Collaborative, Washington, DC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Hewitt","sequence":"additional","affiliation":[{"name":"ASH Research Collaborative, Washington, DC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Plovnick","sequence":"additional","affiliation":[{"name":"ASH Research Collaborative, Washington, DC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa K.","family":"Hicks","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, St. Michael\u2019s Hospital, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,12,5]]},"reference":[{"key":"2020120510304490500_B1","article-title":"WHO Director-General\u2019s opening remarks at the media briefing on COVID-1","author":"World Health Organization","year":"2020"},{"issue":"8","key":"2020120510304490500_B2","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1001\/jama.2020.12839","article-title":"Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review","volume":"324","author":"Wiersinga","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"2020120510304490500_B3","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1016\/S1470-2045(20)30149-2","article-title":"Risk of COVID-19 for patients with cancer","volume":"21","author":"Wang","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"2020120510304490500_B4","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.idc.2019.02.004","article-title":"Respiratory virus infections of the stem cell transplant recipient and the hematologic malignancy patient","volume":"33","author":"Fontana","year":"2019","journal-title":"Infect Dis Clin North Am"},{"issue":"23","key":"2020120510304490500_B5","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood.2020006000","article-title":"COVID-19 and its implications for thrombosis and anticoagulation","volume":"135","author":"Connors","year":"2020","journal-title":"Blood"},{"issue":"23","key":"2020120510304490500_B6","first-page":"I17","article-title":"Venous thromboembolism and cancer: risks and outcomes","volume":"107","author":"Lee","year":"2003","journal-title":"Circulation"},{"key":"2020120510304490500_B7","article-title":"ASH Research Collaborative COVID-19 Registry for Hematology.","author":"ASH Research Collaborative"},{"key":"2020120510304490500_B8","article-title":"Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study [published online ahead of print 13 August 2020]","author":"Passamonti","journal-title":"Lancet Haematol"},{"issue":"10241","key":"2020120510304490500_B9","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","article-title":"Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study [published correction appears in Lancet. 2020;396(10253):758]","volume":"395","author":"Kuderer","year":"2020","journal-title":"Lancet"},{"issue":"10241","key":"2020120510304490500_B10","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0140-6736(20)31173-9","article-title":"COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study","volume":"395","author":"Lee","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"2020120510304490500_B11","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(20)30310-7","article-title":"Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study","volume":"21","author":"Yang","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7","key":"2020120510304490500_B12","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S1470-2045(20)30314-4","article-title":"COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study","volume":"21","author":"Garassino","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"2020120510304490500_B13","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1111\/bjh.16874","article-title":"Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy","volume":"190","author":"Cook","year":"2020","journal-title":"Br J Haematol"},{"issue":"1","key":"2020120510304490500_B14","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/00003246-200301000-00017","article-title":"Outcome and early prognostic indicators in patients with a hematologic malignancy admitted to the intensive care unit for a life-threatening complication","volume":"31","author":"Benoit","year":"2003","journal-title":"Crit Care Med"},{"issue":"4","key":"2020120510304490500_B15","doi-asserted-by":"crossref","first-page":"R194","DOI":"10.1186\/cc2870","article-title":"Performance of six severity-of-illness scores in cancer patients requiring admission to the intensive care unit: a prospective observational study","volume":"8","author":"Soares","year":"2004","journal-title":"Crit Care"},{"issue":"5","key":"2020120510304490500_B16","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s00520-004-0750-y","article-title":"Patients with haematological malignancies requiring invasive mechanical ventilation: differences between survivors and non-survivors in intensive care unit","volume":"13","author":"Owczuk","year":"2005","journal-title":"Support Care Cancer"},{"issue":"9","key":"2020120510304490500_B17","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1179\/1607845414Y.0000000216","article-title":"Prognosis-related factors in intensive care unit (ICU) patients with hematological malignancies: A retrospective cohort analysis in a Chinese population","volume":"20","author":"Liu","year":"2015","journal-title":"Hematology"},{"issue":"5","key":"2020120510304490500_B18","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S2213-2600(20)30161-2","article-title":"Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations [published correction appears in Lancet Respir Med. 2020;8(5):e42]","volume":"8","author":"Phua","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"1","key":"2020120510304490500_B19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13054-020-02891-w","article-title":"Clinical ethics recommendations for the allocation of intensive care treatments in exceptional, resource-limited circumstances: the Italian perspective during the COVID-19 epidemic","volume":"24","author":"Vergano","year":"2020","journal-title":"Crit Care"},{"issue":"24","key":"2020120510304490500_B20","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1002\/cncr.31769","article-title":"Low clinical trial accrual of patients with myelodysplastic syndromes: causes and potential solutions","volume":"124","author":"Steensma","year":"2018","journal-title":"Cancer"},{"key":"2020120510304490500_B21","author":"Institute of Medicine, Board on Health Care Services, Committee on Cancer Clinical Trials and the NCI Cooperative Group Program","year":"2010"},{"issue":"20","key":"2020120510304490500_B22","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","article-title":"Azithromycin and the risk of cardiovascular death","volume":"366","author":"Ray","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"2020120510304490500_B23","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/annonc\/mdv029","article-title":"Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions","volume":"26","author":"van Leeuwen","year":"2015","journal-title":"Ann Oncol"},{"issue":"3","key":"2020120510304490500_B24","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s00280-004-0998-4","article-title":"Potential for drug interactions in hospitalized cancer patients","volume":"56","author":"Riechelmann","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"2020120510304490500_B25","article-title":"Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and Cancer Consortium (CCC19) cohort study [published online ahead of print 22 July 2020]","author":"Rivera","journal-title":"Cancer Discov"},{"issue":"8","key":"2020120510304490500_B26","doi-asserted-by":"crossref","first-page":"e601","DOI":"10.1016\/S2352-3026(20)30205-2","article-title":"Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts","volume":"7","author":"Zeidan","year":"2020","journal-title":"Lancet Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/23\/5966\/1794011\/advancesadv2020003170.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/23\/5966\/1794011\/advancesadv2020003170.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,5]],"date-time":"2020-12-05T15:30:57Z","timestamp":1607182257000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/23\/5966\/474410\/Outcomes-of-patients-with-hematologic-malignancies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,5]]},"references-count":26,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2020,12,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003170","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,5]]}}}